Hydrogen Water Shows Promise for Treating Blood Disorder in Mice

Authors
Journal
Cellular Physiology and Biochemistry
Year
DOI
10.1159/000354459
Study Type
Mouse
Outcome
Positive
Peer Reviewed
Yes
Country
China
Health Condition
Aplastic Anemia
Body System
Hematologic

TL;DR

A hydrogen-rich solution may help treat aplastic anemia by improving blood cell counts and bone marrow health, while also reducing harmful inflammation in mice.

Key Finding

Hydrogen-rich solution treatment in mice with aplastic anemia improved blood cell production, restored bone marrow function, and reduced inflammatory cytokines associated with the disease.

Summary

Aplastic anemia is a serious condition where the bone marrow fails to produce enough blood cells, often due to the immune system attacking stem cells. Researchers gave hydrogen-rich saline to mice with aplastic anemia and found that it improved blood cell counts, restored bone marrow function, and reduced inflammatory chemicals (immune signaling molecules) that contribute to the disease. The treated mice showed better recovery compared to untreated mice with the condition.

Practical Takeaway

This early-stage mouse study suggests hydrogen-rich solution may have potential as a treatment for aplastic anemia by reducing inflammation, but human trials are needed before any clinical application. The findings are preliminary and cannot yet inform treatment decisions for people with this condition.

Abstract

Background: Aplasitc anemia (AA) is a bone marrow failure syndrome characterized by an immune-mediated destruction of hematopoietic stem cells. Though clinical symptoms could be ameliorated by bone marrow transplantation and/or immunosuppressive therapy, frequent recurrence and especially evolution of clonal hematologic diseases remains problematic clinically. Cytokines such as interferon-γ (INF-γ), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) secreted by autologous T cells are closely related with the development of AA. Hydrogen-rich solution was reported to inhibit the levels of cytokines including INF-γ, TNF-α and IL-6 in vivo in recent studies. This study was to investigate the potential therapeutic effects of hydrogen-rich solution on AA in vivo. Methods: AA model was determined in vivo by mice and body weights of the mice were used as the basic physiological index. Peripheral blood cells were calculated to evaluate the hematologic recovery degree. Bone marrow nucleated cells (BMNCs), tissue histology, as well as CFU-S and CFU-GM forming units were used to evaluate the recovery of bone marrow microenvironment. The ratio of CD4(+) and CD8(+) cells were examined along with cytokine levels in serum to determine the efficacy of H2-rich solution on the affected immunological functions. Results: Body weight and number of peripheral blood cells were significantly improved for mice in the H2-rich solution treated groups as compared with those with AA. The number of BMNCs and CFUs increased markedly and the bone marrow microenvironment was also improved significantly. The experimental group restrained the cell apoptosis, relieved hyperemia and accelerated tissue repair. The number of CD4(+) and CD8(+) cells as well as the ratio of CD4/CD8 increased to normal gradually, while the levels of TNF-α, IFN-γ, and IL-6 in serum decreased after H2-rich solution treatment. Conclusion: Our study firstly showed that hydrogen-rich solution accelerated the recovery of either hematological or immunological recovery on aplastic anemia mice. This finding suggests hydrogen-rich solution as a potential clinical therapeutic agent for AA. © 2013 S. Karger AG, Basel.